CAPR
Capricor Therapeutics Inc
8.60$
-1.2%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +4,939.2% | -98.3% | -89.7% | +4,216.0% | -41.1% | -55.7% | +1,394.7% | +406,788.8% | -62.3% | -43.8% | +1.3% | -62.6% | +295.3% | +2.1% | +146.2% | +17.9% | +16.7% | -13.2% | -43.2% | +20.2% | +211.5% | +19.4% | +21.2% | +17.2% | +190.3% | +108.8% | |
| – | – | -98.3% | -89.7% | +4,216.0% | -41.1% | -55.7% | +1,394.7% | +398,942.1% | -63.9% | -43.2% | +4.8% | -63.6% | +296.3% | -29.1% | +215.4% | +20.5% | +29.4% | -13.2% | -46.1% | +24.5% | +219.4% | +8.2% | +17.7% | +18.6% | +221.3% | +97.7% | |
| – | – | -98.8% | -84.0% | +4,216.0% | -41.1% | -55.7% | +1,394.7% | +386,411.0% | -66.1% | -42.3% | +6.4% | -69.2% | -83.6% | +916.7% | +364.6% | +68.9% | +19.4% | -62.1% | -30.6% | -8.5% | +737.7% | +6.8% | -72.5% | +53.0% | -23.2% | +2,450.3% | |
| – | – | -98.8% | -84.0% | +4,216.0% | -41.1% | -55.7% | +1,394.7% | +386,411.0% | -66.1% | -42.3% | +6.4% | -69.2% | +319.8% | -52.9% | +290.8% | +68.9% | +19.4% | -12.8% | -48.6% | +36.2% | +230.4% | +6.8% | +18.7% | -4.7% | +283.7% | +110.0% | |
| – | – | -91.3% | – | – | – | – | – | – | – | – | – | – | – | -100.0% | +192,538.0% | -41.2% | +5.4% | +54.3% | -40.5% | -57.1% | -36.3% | +599.6% | +39.8% | +1,794.2% | 0.0% | -99.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +112.4% | -100.0% | – | -162.8% | – | -330.7% | – | – | +0.0% | +0.0% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -64.2% | +2,026.9% | +209.3% | +38.8% | +36.7% | -14.5% | +54.3% | -22.9% | +92.1% | +442.7% | -0.6% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | -17.1% | -49.0% | – | – | – | +885.5% | -1.0% | -2.8% | -91.6% | -34.6% | +120.2% | -96.8% | +33,233.3% | – | – | – | – | – | |
| – | +0.0% | +920.6% | +167.3% | +70.1% | +42.2% | +31.2% | +73.0% | +1,301.9% | -29.5% | -52.1% | +67.7% | -49.4% | -2.3% | +1,047.6% | +227.4% | -14.0% | +33.0% | -77.8% | -8.2% | -7.7% | +50.2% | +55.2% | +284.5% | -5.7% | -30.8% | +100.5% | |
| – | +0.0% | +920.6% | +167.3% | +70.1% | +42.2% | +31.2% | +73.0% | +1,301.9% | -29.5% | -52.1% | +67.7% | -49.4% | -2.3% | +288.0% | +206.9% | +3.6% | -25.0% | -65.9% | -24.9% | -28.5% | +230.9% | +39.1% | +470.6% | +32.6% | -32.8% | +70.4% | |
| – | – | – | – | +382.6% | +40.7% | +33.5% | +79.7% | – | – | – | – | – | – | – | – | -90.0% | +1,425.7% | – | – | – | – | +69.3% | +63.3% | +9.8% | +11.4% | +334.2% | |
| – | +0.0% | +820.6% | +14.2% | -49.3% | +54.1% | +14.5% | +7.2% | +7,156.8% | +13.2% | -79.8% | +120.7% | +31.7% | -39.5% | +515.4% | +4.3% | +48.9% | +20.1% | -45.0% | -24.9% | -28.5% | +203.4% | +36.4% | +30.1% | +29.1% | -47.4% | -49.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +131.1% | +0.0% | +85.7% | -80.1% | +0.0% | +0.0% | -97.9% | +4,624.0% | +0.0% | – | – | – | |
| – | – | -166.9% | – | – | – | – | – | – | -66.4% | -41.6% | -12.9% | -68.0% | +489.2% | -110.9% | – | – | – | – | -58.9% | +48.2% | +312.3% | +11.2% | -62.4% | +91.8% | +543.6% | +110.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +9.8% | +0.0% | +0.0% | +0.0% | +0.0% | +1,727.0% | +22.8% | +42.4% | +5.6% | +26.3% | +16.0% | +13.1% | +1,144.0% | +11.4% | +36.0% | +16.7% | +44.4% | +9.8% | +26.2% | +319.6% | +48.3% | +6.3% | +9.1% | +31.5% | +32.0% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.